

Laura M Heiser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8774769/publications.pdf>

Version: 2024-02-01

57
papers

5,069
citations

186265
28
h-index

138484
58
g-index

67
all docs

67
docs citations

67
times ranked

9379
citing authors

#	ARTICLE	IF	CITATIONS
1	Theoretical and experimental analysis of negative dielectrophoresis induced particle trajectories. <i>Electrophoresis</i> , 2022, , .	2.4	4
2	A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysis. <i>Communications Biology</i> , 2022, 5, 255.	4.4	20
3	A scalable, open-source implementation of a large-scale mechanistic model for single cell proliferation and death signaling. <i>Nature Communications</i> , 2022, 13, .	12.8	12
4	A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. <i>Nature Biotechnology</i> , 2022, 40, 1823-1833.	17.5	17
5	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. <i>Npj Precision Oncology</i> , 2021, 5, 28.	5.4	19
6	Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. <i>Breast Cancer Research</i> , 2021, 23, 81.	5.0	7
7	Integrating Mathematical Modeling with High-Throughput Imaging Explains How Polyploid Populations Behave in Nutrient-Sparse Environments. <i>Cancer Research</i> , 2020, 80, 5109-5120.	0.9	8
8	Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa093.	0.7	5
9	Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. <i>Scientific Reports</i> , 2020, 10, 21750.	3.3	34
10	Automatic Transformation and Integration to Improve Visualization and Discovery of Latent Effects in Imaging Data. <i>Journal of Computational and Graphical Statistics</i> , 2020, 29, 929-941.	1.7	7
11	How Machine Learning Will Transform Biomedicine. <i>Cell</i> , 2020, 181, 92-101.	28.9	279
12	A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. <i>Cell Systems</i> , 2019, 9, 35-48.e5.	6.2	95
13	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2318-2330.	3.4	41
14	Systems biology approaches to measure and model phenotypic heterogeneity in cancer. <i>Current Opinion in Systems Biology</i> , 2019, 17, 35-40.	2.6	17
15	Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	16
16	BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. <i>Oncogene</i> , 2019, 38, 5658-5669.	5.9	23
17	Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. <i>Cancer Cell</i> , 2019, 35, 341-343.	16.8	7
18	Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2019, 9, 3823.	3.3	32

#	ARTICLE	IF	CITATIONS
19	Annot: a Django-based sample, reagent, and experiment metadata tracking system. BMC Bioinformatics, 2019, 20, 542.	2.6	1
20	Individual Cells Can Resolve Variations in Stimulus Intensity along the IGF-PI3K-AKT Signaling Axis. Cell Systems, 2019, 9, 580-588.e4.	6.2	20
21	Variational autoencoding tissue response to microenvironment perturbation. , 2019, 10949, .		2
22	The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. Cell Systems, 2018, 6, 13-24.	6.2	327
23	Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Systems, 2018, 6, 329-342.e6.	6.2	72
24	Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Systems, 2017, 4, 73-83.e10.	6.2	41
25	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clinical Cancer Research, 2017, 23, 5123-5134.	7.0	85
26	Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. Genome Medicine, 2017, 9, 40.	8.2	16
27	Combating subclonal evolution of resistant cancer phenotypes. Nature Communications, 2017, 8, 1231.	12.8	124
28	Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2892-2901.	4.1	35
29	MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications, 2017, 8, 1728.	12.8	83
30	Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Scientific Data, 2017, 4, 170166.	5.3	34
31	Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget, 2017, 8, 111084-111095.	1.8	11
32	Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Research, 2016, 18, 70.	5.0	11
33	FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6600-E6609.	7.1	119
34	PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder. Scientific Reports, 2016, 6, 31750.	3.3	33
35	Inferring causal molecular networks: empirical assessment through a community-based effort. Nature Methods, 2016, 13, 310-318.	19.0	209
36	Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Molecular Cancer Research, 2016, 14, 3-13.	3.4	230

#	ARTICLE	IF	CITATIONS
37	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. <i>Oncotarget</i> , 2016, 7, 40690-40703.	1.8	12
38	Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor. <i>Journal of Clinical Oncology</i> , 2016, 34, e16538-e16538.	1.6	0
39	A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. <i>Frontiers in Genetics</i> , 2015, 6, 341.	2.3	9
40	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3995-4003.	7.0	82
41	Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0133219.	2.5	19
42	Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. <i>Breast Cancer Research</i> , 2014, 16, 430.	5.0	61
43	A community computational challenge to predict the activity of pairs of compounds. <i>Nature Biotechnology</i> , 2014, 32, 1213-1222.	17.5	264
44	A community effort to assess and improve drug sensitivity prediction algorithms. <i>Nature Biotechnology</i> , 2014, 32, 1202-1212.	17.5	653
45	A robust prognostic signature for hormone-positive node-negative breast cancer. <i>Genome Medicine</i> , 2013, 5, 92.	8.2	18
46	Metrics other than potency reveal systematic variation in responses to cancer drugs. <i>Nature Chemical Biology</i> , 2013, 9, 708-714.	8.0	280
47	Modeling precision treatment of breast cancer. <i>Genome Biology</i> , 2013, 14, R110.	9.6	264
48	A Central Role for RAF ⁺ MEK ⁺ ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma. <i>Cancer Discovery</i> , 2012, 2, 685-693.	9.4	264
49	Subtype and pathway specific responses to anticancer compounds in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2724-2729.	7.1	417
50	ATM Suppresses SATB1-Induced Malignant Progression in Breast Epithelial Cells. <i>PLoS ONE</i> , 2012, 7, e51786.	2.5	20
51	Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition. <i>Cancer Research</i> , 2009, 69, 565-572.	0.9	340
52	Integrated analysis of breast cancer cell lines reveals unique signaling pathways. <i>Genome Biology</i> , 2009, 10, R31.	9.6	56
53	Dynamic Circuitry for Updating Spatial Representations. III. From Neurons to Behavior. <i>Journal of Neurophysiology</i> , 2007, 98, 105-121.	1.8	26
54	Spatial Updating in Area LIP Is Independent of Saccade Direction. <i>Journal of Neurophysiology</i> , 2006, 95, 2751-2767.	1.8	78

#	ARTICLE	IF	CITATIONS
55	Dynamic Circuitry for Updating Spatial Representations. II. Physiological Evidence for Interhemispheric Transfer in Area LIP of the Split-Brain Macaque. <i>Journal of Neurophysiology</i> , 2005, 94, 3249-3258.	1.8	32
56	Dynamic Circuitry for Updating Spatial Representations. I. Behavioral Evidence for Interhemispheric Transfer in the Split-Brain Macaque. <i>Journal of Neurophysiology</i> , 2005, 94, 3228-3248.	1.8	28
57	Corollary discharge and spatial updating: when the brain is split, is space still unified?. <i>Progress in Brain Research</i> , 2005, 149, 187-205.	1.4	25